Request Demo

Last update 20 Mar 2025

Nitrocaphane

Last update 20 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [4]

Active Indication

AscitesBone Marrow NeoplasmsEsophageal Carcinoma+ [3]

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC14H19Cl2N3O4

InChIKeyVEBTZMUIBMIPCD-UHFFFAOYSA-N

CAS Registry54940-95-3

100 Clinical Results associated with Nitrocaphane

100 Translational Medicine associated with Nitrocaphane

100 Patents (Medical) associated with Nitrocaphane

Literatures (Medical) associated with Nitrocaphane

01 Apr 2007·Chinese Medical JournalQ3 · MEDICINE

Protective effect of O6-methylguanine-DNA-methyltransferase on mammalian cells

Q3 · MEDICINE

ArticleOA

Author: Li, Wei-da ; Li, Dong-bo ; Fang, Qin ; Xu, Wei ; Wang, Ji-shi ; Sun, Hai-yang

BACKGROUNDO(6)-methylguanine-DNA-methyltransferase (MGMT) is a specific DNA revising enzyme transferring alkylated groups from DNA to its cysteine residue to avoid the abnormal twisting of DNA. Therefore, it is one of the drug resistant genes targeted in the treatment of cancer. This study explored the protective effect of MGMT gene transferred into mammalian cells.METHODSMammalian expression vector containing the MGMT gene cloned from human hepatocytes by RT-PCR was constructed and transferred into K562 cells and human peripheral blood mononuclear cells (PBMCs) via liposome, then assayed for gene expression at RNA and protein levels. MTT assay was used to check the drug resistance of cells transfected with MGMT gene.RESULTSMGMT gene was successfully cloned. Real-time PCR showed that the mRNA expression in gene transfected groups in K562 cell line and PBMC were 13.4 and 4.0 times that of the empty vector transfected groups respectively.RESULTSof Western blotting showed distinct higher expression of MGMT in gene transfected group than in other two groups. The IC(50) values increased to 7 and 2 times that of the original values respectively in stable transfected K562 cells and transient transfected PBMC.CONCLUSIONThe alkylating resistance of eukaryotic cells is enhanced after being transfected with MGMT gene which protein product performs the protective function, and may provide the reference for the protective model of peripheral blood cells in cancer chemotherapy.

01 Oct 2001·Gynecologic OncologyQ2 · MEDICINE

Pregnancy Outcomes of Patients Who Conceived within 1 Year after Chemotherapy for Gestational Trophoblastic Tumor: A Clinical Report of 22 Patients

Q2 · MEDICINE

Review

Author: Song Hongzhao ; Zhu Lan ; Xiang Yang ; Yang Xiuyu

OBJECTIVEThe aim of this study was to explore the risk of pregnancy of patients who conceived within 1 year after successful chemotherapy for gestational trophoblastic tumor (GTT).METHODSFrom 1966 to 1996, 22 patients who conceived within 1 year after chemotherapy were followed up and analyzed retrospectively.RESULTSAmong 22 patients, 9 had term deliveries and 1 had a premature birth, 6 had induced abortion at the patient's request, and 6 had therapeutic abortion because of various indications such as repeated hydatidiform mole (1 case), intrauterine death (1 case), inevitable abortion (1 case), and threatened abortion (3 cases). The fetal loss rate was 27.1% (6/22). The incidence rate of gestational trophoblastic disease (GTD) was 9.1% (2/22). The incidence rate of GTT was 4.5% (1/22). The average interval between completion of chemotherapy and pregnancy was 10.25 months in the group of term pregnancies and 5.86 months in that of fetal loss (P < 0.05), indicating that the longer the interval, the lesser the risk of GTD.CONCLUSIONThe results suggest that contraception for 1 year is necessary in patients with GTT after successful chemotherapy. However, in the case of a patient who conceives within 1 year, it is not necessary to terminate pregnancy, but the pregnancy must be carefully watched.

01 Dec 1998·Gynecologic OncologyQ2 · MEDICINE

Chemotherapy Using 5-Fluorouracil and Nitrocaphanum in Malignant Trophoblastic Tumor

Q2 · MEDICINE

Article

Author: Daping Qiu ; Ling Jiu ; Yixun Wang ; Yulan Guan

OBJECTIVEThe aim of this study was to investigate the efficacy of nitrocaphanum (AT 1258) in combination with 5-fluorouracil (5-FU) in patients with gestational trophoblastic tumors (GTT).METHODFrom 1979 to 1988, 152 patients with trophoblastic tumor were treated with combination chemotherapy using nitrocaphanum and 5-FU. Seventy patients had nonmetastatic disease, 61 with single organ metastasis and 9 with involvement of two or more organs. Fifty patients had received previous chemotherapy. The dose of 5-FU was 26 mg/kg and that of nitrocaphanum 0.6 mg/kg each daily for 8 days, repeated every 29 days.RESULTSAmong patients who received nitrocaphanum with 5-FU, 134 of 152 patients (88%) achieved remission. By World Health Organization risk groups, the response to nitrocaphanum was as follows: 5-FU was 93.6% of 94 low-risk patients, 81.4% of 46 medium-risk patients, and 73.3% of 15 high-risk patients. Eighteen patients had to be given a second-line protocol because of resistance to nitrocaphanum and 5-FU. Fourteen of the 18 were cured while 4 patients died. There were 7 late recurrences more than 3 months after completion of therapy and 6 of these were cured by hysterectomy and chemotherapy.CONCLUSIONNitrocaphanum is an active chemotherapy agent in GTT and deserves further study for possible use in high-risk, chemotherapy-resistant patients.

100 Deals associated with Nitrocaphane

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ascites	China	-	-
Bone Marrow Neoplasms	China	-	-
Esophageal Carcinoma	China	-	-
Lymphoma	China	-	-
Nasopharyngeal Carcinoma	China	-	-
Seminoma	China	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Nitrocaphane

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation